Improved Delivery and Function of Myoblasts via Soluble TIPS Microcarriers
Lead Research Organisation:
University College London
Department Name: Medicine
Abstract
Incontinence is a debilitating condition with devastating social, economic and psychological consequences. A common cause is damage sustained during childbirth to the muscles that normally provide control of bowel movements. Current medical and surgical treatments are often inadequate. Emerging treatments involving the use of a patient's own muscle cells offer the possibility of restoring function to the damaged muscle, but improved methods for delivering the cells to ensure they survive and repair tissue are needed.
The aim of the proposed research is to demonstrate, through proof of principle, that muscle cells attached to the surface of a unique type of degradable polymer microsphere are more effective at restoring injured muscle compared with conventional methods of muscle cell delivery. The aim will be achieved through an interdisciplinary project involving biologists, clinicians and materials scientists. The experimental study will include investigating the optimal conditions for attachment of muscle cells to the microspheres; delivery of the cellularized microspheres to pre-clinical models of muscle injury; measurement of integration of the transplanted cells at the injury site; and ability of the transplanted cells to restore muscle contractility. In parallel to the experimental study we will establish women's views on the innovative therapy we are proposing, which will help us to design a therapeutic system best suited to the user's needs.
The outcome from the present study will provide timely, key information for the future development of the therapeutic system. The experimental outputs will be used to design future clinical trials investigating the safety and effectiveness of the treatment in faecally incontinent patients. Both the polymer microspheres and cell types being investigated are already being developed independently for other clinical uses, making transfer of findings from this project to the clinic for faecal incontinence much faster. If successful, the therapeutic system will have tremendous economic benefits to the UK NHS, as well as delivering social, economic and psychological benefits to patients.
The aim of the proposed research is to demonstrate, through proof of principle, that muscle cells attached to the surface of a unique type of degradable polymer microsphere are more effective at restoring injured muscle compared with conventional methods of muscle cell delivery. The aim will be achieved through an interdisciplinary project involving biologists, clinicians and materials scientists. The experimental study will include investigating the optimal conditions for attachment of muscle cells to the microspheres; delivery of the cellularized microspheres to pre-clinical models of muscle injury; measurement of integration of the transplanted cells at the injury site; and ability of the transplanted cells to restore muscle contractility. In parallel to the experimental study we will establish women's views on the innovative therapy we are proposing, which will help us to design a therapeutic system best suited to the user's needs.
The outcome from the present study will provide timely, key information for the future development of the therapeutic system. The experimental outputs will be used to design future clinical trials investigating the safety and effectiveness of the treatment in faecally incontinent patients. Both the polymer microspheres and cell types being investigated are already being developed independently for other clinical uses, making transfer of findings from this project to the clinic for faecal incontinence much faster. If successful, the therapeutic system will have tremendous economic benefits to the UK NHS, as well as delivering social, economic and psychological benefits to patients.
Technical Summary
The project aims to demonstrate proof of principle for an innovative therapeutic system for functional restoration of injured muscle using a combination of cell therapy and a novel degradable cell microcarrier device. The novelty of this approach is the use of TIPS microspheres for cell expansion and delivery, utilizing their advantageous features and avoiding the need for proteolytic cell detachment prior to delivery.
Optimal conditions for muscle progenitor cell attachment to TIPS microspheres with different porosities will be identified with primary cultures of myoblasts and mesoangioblasts derived from mouse and human tissues at different seeding densities using a range of dynamic and/or static regimens. External anal sphincter injury will be modelled in a pilot investigation by creating a transverse incision in the tibialis anterior of mice and evaluating the healing response. Delivery of the cellularized microspheres and repair of muscle injury will be investigated in three injury groups simulating repair at different stages after obstetric injury and compared with delivery of cell suspensions or microspheres alone. The muscle will be resected at 2 and 4 weeks after treatment and contractile properties measured using an organ bath and electrical field stimulation. Integration of transplanted cells with host muscle at the injury site and remodelling of tissue will be determined by histology combined with morphometric analysis of fibrosis and angiogenesis.
The findings from the experimental component of the project, combined with feedback from patient user groups, will contribute to the developmental pathway of the therapeutic system. The use of quality qualified TIPS microspheres combined with cell types currently being trialled in humans as advanced therapeutic medicinal products will accelerate future translation of the system into the clinic.
Optimal conditions for muscle progenitor cell attachment to TIPS microspheres with different porosities will be identified with primary cultures of myoblasts and mesoangioblasts derived from mouse and human tissues at different seeding densities using a range of dynamic and/or static regimens. External anal sphincter injury will be modelled in a pilot investigation by creating a transverse incision in the tibialis anterior of mice and evaluating the healing response. Delivery of the cellularized microspheres and repair of muscle injury will be investigated in three injury groups simulating repair at different stages after obstetric injury and compared with delivery of cell suspensions or microspheres alone. The muscle will be resected at 2 and 4 weeks after treatment and contractile properties measured using an organ bath and electrical field stimulation. Integration of transplanted cells with host muscle at the injury site and remodelling of tissue will be determined by histology combined with morphometric analysis of fibrosis and angiogenesis.
The findings from the experimental component of the project, combined with feedback from patient user groups, will contribute to the developmental pathway of the therapeutic system. The use of quality qualified TIPS microspheres combined with cell types currently being trialled in humans as advanced therapeutic medicinal products will accelerate future translation of the system into the clinic.
Planned Impact
The project aims to enhance development and translation of a new treatment strategy to the clinic. The project will provide impact in several of the MRC strategic priority areas including delivery of new regenerative medicine products for treatment of disease (Research Priority Theme One; Strategic Aim Two), generation of positive economic impact (Strategic Aim One), and strengthening a skilled research workforce (Strategic Aim Four).
In the short-term (1-3 years), beneficiaries will include companies in the cell therapy industry, especially those that are beginning to explore the untapped market for faecal incontinence (FI). The cell types being investigated are already used as advanced therapeutic medicinal products in commercially-sponsored clinical trials for a variety of clinical conditions. However, existing pre-clinical and clinical data indicate improved methods are sought for delivery of cells. Successful outcomes from this project, combined with TIPS microspheres being quality qualified independently, will deliver a pre-clinically qualified device in readiness for partnership or out-licensing to cell therapy companies for clinical validation of an innovative product in humans and help foster UK economic competitiveness.
In the mid-term (3-5 years), the aim is to verify efficacy of the therapeutic system for delivering cells for the treatment of FI. Successful clinical validation of the therapeutic system will reduce the current economic and social burden of incontinence on the UK NHS and patient community. Although the primary beneficiaries from this project will be patients with FI caused by non-neurogenic damage to anal sphincter muscle, other beneficiaries of the technology will include patients with FI caused by primary degeneration of sphincter muscle. In addition to FI, the therapeutic system will also provide technology of potential value to other conditions associated with muscle insufficiency or where delivery of cells on TIPS microcarriers may prove advantageous e.g. Duchenne muscular dystrophy. Therefore, the intellectual property relating to further development of the device holds significant value for commercialisation. Dissemination of the project findings will help underpin a drive for innovative cell-based therapeutic interventions for this and other clinical conditions, thus boosting the UK economy.
In the longer-term (>5 years), after efficacy for repair of overt sphincter damage with the therapeutic system has been demonstrated, it is feasible to envisage it being applied to the prevention of incontinence in patients who have detectable sphincter disruption (based on future wider adoption of improved ultrasound imaging technology), but who do not currently experience symptoms. The patient perception of this type of approach will be ascertained from the patient participant focus group in the current project. Combined with clinical input for use, these data will influence design of the system and contribute to it meeting requirements of regulatory authorities.
The project will provide the PDRA with an excellent opportunity to develop career skills in a multidisciplinary environment at the laboratory-clinic interface, as well as gaining an insight into the translation pathway from bench-to-bedside. The project will equip the person with the breadth of skills needed to effectively understand the processes involved with developing new healthcare products and provide them with experience of how to establish links and subsequently work with industrial partners as the technology moves forward. These career development opportunities go beyond those typically offered in a pre-clinical research project and will provide the PDRA with key attributes highly sought after for academic-industrial partnerships, adding a skilled scientist to the burgeoning UK med-tech industry work force.
In the short-term (1-3 years), beneficiaries will include companies in the cell therapy industry, especially those that are beginning to explore the untapped market for faecal incontinence (FI). The cell types being investigated are already used as advanced therapeutic medicinal products in commercially-sponsored clinical trials for a variety of clinical conditions. However, existing pre-clinical and clinical data indicate improved methods are sought for delivery of cells. Successful outcomes from this project, combined with TIPS microspheres being quality qualified independently, will deliver a pre-clinically qualified device in readiness for partnership or out-licensing to cell therapy companies for clinical validation of an innovative product in humans and help foster UK economic competitiveness.
In the mid-term (3-5 years), the aim is to verify efficacy of the therapeutic system for delivering cells for the treatment of FI. Successful clinical validation of the therapeutic system will reduce the current economic and social burden of incontinence on the UK NHS and patient community. Although the primary beneficiaries from this project will be patients with FI caused by non-neurogenic damage to anal sphincter muscle, other beneficiaries of the technology will include patients with FI caused by primary degeneration of sphincter muscle. In addition to FI, the therapeutic system will also provide technology of potential value to other conditions associated with muscle insufficiency or where delivery of cells on TIPS microcarriers may prove advantageous e.g. Duchenne muscular dystrophy. Therefore, the intellectual property relating to further development of the device holds significant value for commercialisation. Dissemination of the project findings will help underpin a drive for innovative cell-based therapeutic interventions for this and other clinical conditions, thus boosting the UK economy.
In the longer-term (>5 years), after efficacy for repair of overt sphincter damage with the therapeutic system has been demonstrated, it is feasible to envisage it being applied to the prevention of incontinence in patients who have detectable sphincter disruption (based on future wider adoption of improved ultrasound imaging technology), but who do not currently experience symptoms. The patient perception of this type of approach will be ascertained from the patient participant focus group in the current project. Combined with clinical input for use, these data will influence design of the system and contribute to it meeting requirements of regulatory authorities.
The project will provide the PDRA with an excellent opportunity to develop career skills in a multidisciplinary environment at the laboratory-clinic interface, as well as gaining an insight into the translation pathway from bench-to-bedside. The project will equip the person with the breadth of skills needed to effectively understand the processes involved with developing new healthcare products and provide them with experience of how to establish links and subsequently work with industrial partners as the technology moves forward. These career development opportunities go beyond those typically offered in a pre-clinical research project and will provide the PDRA with key attributes highly sought after for academic-industrial partnerships, adding a skilled scientist to the burgeoning UK med-tech industry work force.
Publications
Maffioletti SM
(2014)
Stem cell transplantation for muscular dystrophy: the challenge of immune response.
in BioMed research international
Maffioletti SM
(2018)
Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering.
in Cell reports
Tedesco FS
(2015)
Human artificial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes.
in Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology
Parmar N
(2015)
TIPS to manipulate myogenesis: retention of myoblast differentiation capacity using microsphere culture.
in European cells & materials
Hendow EK
(2016)
Biomaterials for hollow organ tissue engineering.
in Fibrogenesis & tissue repair
Wright B
(2015)
A simple and robust method for pre-wetting poly (lactic-co-glycolic) acid microspheres.
in Journal of biomaterials applications
Malik SA
(2016)
Electrospray synthesis and properties of hierarchically structured PLGA TIPS microspheres for use as controlled release technologies.
in Journal of colloid and interface science
Wright B
(2016)
Women's views on autologous cell-based therapy for post-obstetric incontinence.
in Regenerative medicine
Parmar N
(2015)
A novel method for differentiation of human mesenchymal stem cells into smooth muscle-like cells on clinically deliverable thermally induced phase separation microspheres.
in Tissue engineering. Part C, Methods
Title | Sculptural works around regenerative medicine technologies |
Description | Elpida Hadzi-Vasileva is a contemporary artist who has produced a series of sculptural works around regenerative medicine technologies, including the TIPS microparticles (http://elpihv.co.uk/works/making-beauty2 - slide show images 12 & 13) |
Type Of Art | Artwork |
Year Produced | 2016 |
Impact | Elpida Hadzi-Vasileva is a contemporary artist who has produced a series of sculptural works around regenerative medicine technologies, including the TIPS microparticles. |
URL | http://elpihv.co.uk/works/making-beauty2 |
Description | Co-organiser, Myopathology Symposium |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
URL | https://www.bns.org.uk/event/3052-2/ |
Description | UK Academic Foundation Programme Interview Panel, London, 2019 |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Interview panel member of the prestigious UK Academic Foundation Programme. The Academic Foundation Programme is a clinical specialty training providing an opportunity for foundation doctors to develop research, teaching and leadership/management skills in addition to the clinical competences outlined in the Foundation Programme Curriculum. |
URL | https://foundationprogramme.nhs.uk/programmes/2-year-foundation-programme/academic-training/ |
Description | A Novel Drug-Device Adjuvant Treatment for Radical Prostatectomy |
Amount | £194,946 (GBP) |
Funding ID | A22105 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2017 |
End | 06/2019 |
Description | AMELIE (Anchored Muscle cELls for IncontinEnce) |
Amount | € 952,609,725 (EUR) |
Organisation | European Commission H2020 |
Sector | Public |
Country | Belgium |
Start | 08/2020 |
End | 08/2025 |
Description | BHF PhD studentship TIPS microspheres in cardiovascular disease |
Amount | £70,000 (GBP) |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2014 |
End | 10/2018 |
Description | Biomaterial-Based Therapeutic Neovascularization |
Amount | £204,681 (GBP) |
Funding ID | PG/16/56/32246 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2017 |
End | 06/2019 |
Description | In vivo modelling of Duchenne muscular dystrophy using patient-specific iPS cell-derived artificial muscles for therapy development" |
Amount | € 25,000 (EUR) |
Organisation | Duchenne Parent Project Holland |
Sector | Charity/Non Profit |
Country | Netherlands |
Start | 08/2019 |
End | 08/2020 |
Description | Multimodal Comparative Study of Human iPSC-Derived and Primary Skeletal Muscle Progenitor Cells |
Amount | £39,000 (GBP) |
Funding ID | CiC019 |
Organisation | King's College London |
Department | London Advanced Therapies |
Sector | Academic/University |
Country | United Kingdom |
Start | 06/2020 |
End | 07/2021 |
Description | Particle Delivery of Oxidative Biocides for Therapeutic Purposes |
Amount | £280,000 (GBP) |
Organisation | Gamma Healthcare |
Sector | Private |
Country | United States |
Start | 09/2016 |
End | 01/2017 |
Description | Proof-of-concept award |
Amount | £25,000 (GBP) |
Organisation | UCL Business |
Sector | Private |
Country | United Kingdom |
Start | 11/2014 |
End | 03/2015 |
Description | Refined Manufacturing and Process Development of TIPS Particle Technology |
Amount | £110,000 (GBP) |
Organisation | National Institute for Health Research |
Department | UCLH/UCL Biomedical Research Centre |
Sector | Academic/University |
Country | United Kingdom |
Start | 12/2014 |
End | 12/2016 |
Description | Refined Manufacturing and Process Development of TIPS Particle Technology |
Amount | £183,236 (GBP) |
Organisation | National Institute for Health Research |
Department | UCLH/UCL Biomedical Research Centre |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2016 |
End | 11/2017 |
Description | Regenerative Medicine Research Committee |
Amount | £214,234 (GBP) |
Funding ID | MR/R014108/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2018 |
End | 01/2019 |
Description | TIPS microspheres for a novel antimicrobial release system aimed at tackling antimicrobial resistance |
Amount | £60,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Department | MRC Confidence in Concept Scheme |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2014 |
End | 09/2015 |
Description | TIPS microspheres in cardiovascular disease |
Amount | £20,000 (GBP) |
Organisation | Bristol Heart Institute |
Sector | Hospitals |
Country | United Kingdom |
Start | 06/2014 |
End | 07/2015 |
Description | UK Regenerative Medicine Platform Hub Partnership Award |
Amount | £65,642 (GBP) |
Organisation | UKRMP Acellular Hub and UKRMP Immunomodulation Hub (Delcassian) |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2014 |
End | 08/2017 |
Title | Patient and public perceptions of novel regenerative medicine therapies. |
Description | We have devised a novel questionnaire to gain perceptions on the proposed novel therapy involving cell therapy and regenerative medicine. This involves patient and public involvement (PPI) and includes collaboration between clinical teams at UCL H. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2014 |
Provided To Others? | Yes |
Impact | We have completed collecting the data with the questionaaire for analysis. The results have provided a clear insight into how the general public perceive and understand our research. The results have now been published: • Wright B, Emmanuel A, Athanasakos E, Parmar N, Parker G, Green B, Tailby E, Chandler H, Cushnie J, Pembroke J, Saruchera Y, Vashisht A, Day R. (2016) Women's Views on Autologous Cell-Based Therapy for Post-Obstetric Incontinence. Regenerative Medicine (in press). doi:10.2217/rme.15.88 |
Title | Precision attachment & storage of cells on microcarriers |
Description | Recent advances in biotechnology have introduced the possibility of new therapies based on either the delivery of cells or isolation of their biological derivatives. Adherent cells are those that exist in a native state attached to surrounding tissues. When isolated from their normal environment adherent cells require an artificial substrate in order to grow and divide in vitro. Adherent cells are being explored as novel therapies for a variety of conditions as well for drug discovery as replacements for animal models to screen new compounds, or for the production of biological materials, such as enzymes, vaccines, hormones, antibodies, interferons and nucleic acids. Conventional methods used for manufacturing and storage of adherent cells are sub-optimal for many of the new uses, where delivery of precise quantities of viable and potent cells is often required. Microcarriers are being increasingly explored for the expansion of adherent cells as an alternative to conventional 2D tissue culture substrates. However, two interlinked stages frequently used during the manufacturing process of adherent cell products pose particular risks to the viability and potency of the product: The first risk occurs if there is a need for initial detachment of cells from the culture substrate, which poses a critical risk to the viability of the cells and their ultimate function. The second risk occurs if the cells require cryopreservation during the transfer from the manufacturer to the end user, with cryopreservation and cell thawing having an impact on cell survival. To address these challenges we have developed novel clinically ready, biodegradable, biocompatible synthetic microcarriers (TIPS microparticles) that eliminate the need for cell detachment before clinical delivery. Our pre-clinical studies have demonstrated this approach is technically feasible and the technology is currently being translated to early stage clinical studies. Building on this, our pilot studies have demonstrated that cells attached to the biodegradable microcarriers are compatible with cryopreservation, with viable cells remaining attached to the microcarriers after thawing. We hypothesize that the microcarriers offer a feasible solution to mitigate the risks associated with the manufacture of adherent cell based products used in biotechnology. Since existing methods for seeding adherent cells onto microcarriers are unpredictable and inconsistent we have devised a novel process that involves incubating individual microcarriers with a specific quantity of cells in a droplet of liquid. To date, our pilot studies have demonstrated this approach is technically feasible but have involved the use of manual dispensing of cells and microcarriers into the hanging drop. To make the technology attractive for industrial applications, we hypothesize this approach could be scaled-up and automated to provide a process capable of producing large quantities of cellularized microcarriers, each with a specified quantity of cells attached to the surface. |
Type Of Material | Technology assay or reagent |
Provided To Others? | No |
Impact | We are in the process of filing a patent application on the technology outlined above. |
Title | Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles |
Description | Generating human skeletal muscle models is instrumental for investigating muscle pathology and therapy. Here, we report the generation of three-dimensional (3D) artificial skeletal muscle tissue from human pluripotent stem cells, including induced pluripotent stem cells (iPSCs) from patients with Duchenne, limb-girdle, and congenital muscular dystrophies. 3D skeletal myogenic differentiation of pluripotent cells was induced within hydrogels under tension to provide myofiber alignment. Artificial muscles recapitulated characteristics of human skeletal muscle tissue and could be implanted into immunodeficient mice. Pathological cellular hallmarks of incurable forms of severe muscular dystrophy could be modeled with high fidelity using this 3D platform. Finally, we show generation of fully human iPSC-derived, complex, multilineage muscle models containing key isogenic cellular constituents of skeletal muscle, including vascular endothelial cells, pericytes, and motor neurons. These results lay the foundation for a human skeletal muscle organoid-like platform for disease modeling, regenerative medicine, and therapy development. |
Type Of Material | Model of mechanisms or symptoms - human |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | 1) 1.5EUR million ERC Starting Grant 2) Promotion to Full Professor 3) Group Leader at Francis Crick Insitute |
URL | https://www.sciencedirect.com/science/article/pii/S2211124718304522?via%3Dihub |
Description | Force Generation Studies with Prof Dominic Wells at Royal Veterinary College |
Organisation | Royal Veterinary College (RVC) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have developed an in vivo injury model designed to assess the potency of the advanced therapeutic medicinal products being developed. |
Collaborator Contribution | A method for evaluating the regeneration of muscle, in terms for force generation, has been validated for use with the advanced therapeutic medicinal products being developed. |
Impact | The collaboration is multi-disciplinary, involving cell biology, materials science and surgery. |
Start Year | 2014 |
Description | Investigation of muscle regenerative therapies |
Organisation | Cook Myosite Inc |
Country | United States |
Sector | Private |
PI Contribution | Evaluation of compatibility of Cook Myosite cell products and reagents with our cell manufacturing technology. |
Collaborator Contribution | Provision of research materials and insight into industry requirements. |
Impact | Multidisciplinary collaboration between cell biologists, biomedical engineers and bioprocessing experts. |
Start Year | 2016 |
Description | Investigation of muscle regenerative therapies |
Organisation | Merck |
Department | MilliporeSigma |
Country | United States |
Sector | Private |
PI Contribution | Development of novel manufacturing processes for cell based medicines. |
Collaborator Contribution | Insight into industry requirements. |
Impact | Multidisciplinary collaboration between cell biologists, biomedical engineers and bioprocessing experts. |
Start Year | 2016 |
Description | Investigation of muscle regenerative therapies |
Organisation | Plasticell Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | Provision of research materials to evaluate their potential use in controlled delivery of active ingredients. |
Collaborator Contribution | Verification of human induced pluripotent stem cell attachment to TIPS microparticles. |
Impact | A collaborative project with Plasticell Ltd, an SME based at the Stevenage Bioscience Catalyst site, is investigating the use of TIPS microspheres to assist with their proprietary technology differentiating human induced pluripotent stem cells into myogenic progenitors and the controlled delivery of inducers of muscle differentiation they have discovered through screening of GSK small molecule libraries. A joint funding application has entered the second stage of the Technology Strategy Board's Advancing Regenerative Medicines and Cell Therapies scheme. |
Start Year | 2014 |
Description | Research Collaboration with Dr Daniel Stuckey at UCL Centre for Advanced Biomedical Imaging |
Organisation | University College London |
Department | Department of Geography |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Access to research models that highlight the value of advanced biomedical imaging modalities. |
Collaborator Contribution | The new collaboration has enabled the application of non-destructive imaging and tracking of cellularized biomaterial constructs being explored in our research. |
Impact | Research publication being prepared. |
Start Year | 2015 |
Company Name | Luna Therapeutics |
Description | |
Year Established | 2020 |
Impact | Too early to report this. |
Website | http://luna-tx.com/ |
Description | - Muscular Dystrophy UK research strategy reviewing panel, Jan 2018 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | Muscular Dystrophy UK research strategy reviewing panel |
Year(s) Of Engagement Activity | 2018 |
Description | AFM-Telethon Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited presentation at AFM-Telethon Myology 2022 Conference, Nice (FR), Sep 2022 |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.myology2022.org |
Description | All Party Parliamentary Group for Continence Care,House of Lord's (London, UK) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Policymakers/politicians |
Results and Impact | Discussion on continence care and how new technologies including regenerative medicine might benefit this. |
Year(s) Of Engagement Activity | 2014 |
Description | Apollo Society London, launching event |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Apollo Society London (launching event). Please see: http://london.apollosociety.eu |
Year(s) Of Engagement Activity | 2018 |
URL | http://london.apollosociety.eu |
Description | EDANA (international association for the nonwovens and related industries) Outlook conference (Barcelona, Spain) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Invited lecture on biomaterials and incontinence. Established new links with industry. |
Year(s) Of Engagement Activity | 2014 |
Description | Invited Talk Tissue and Cell Engineering Society/UK Regenerative Medicine Platform Hub Meeting, Newcastle, UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Invited talk on TIPS microsphere technology. Further collaborations established using TIPS microspheres. |
Year(s) Of Engagement Activity | 2014 |
Description | Invited presentation at ISSCR 2018 conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | International Society for Stem Cell Research (ISSCR) annual conference, Melbourne (AU), Jun 2018 |
Year(s) Of Engagement Activity | 2018 |
Description | Invited presentation at Kyoto University |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Professional Practitioners |
Results and Impact | Center for iPS Cell Research and Application (CiRA), Kyoto University (JP), Sep 2018 |
Year(s) Of Engagement Activity | 2018 |
Description | Key note lecture TERM STEM 2015 (Guimarães, Portugal) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | To present data from project and engage with fellow researchers. New collaborations have arisen from this activity. |
Year(s) Of Engagement Activity | 2015 |
Description | Oral presentation to UCL graduate and undergraduate students |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Annual seminars on muscle stem cells and regeneration in three separate UCL modules: 1) "Stem Cells and Regenerative Medicine" (CELL3001), 2014 onwards; 2) "Stem Cells and Tissue Repair" (CHLDGG04), MSc in Gene & Cell Therapy, 2013 onwards; 3) "Tissue Engineering" (MECHGB07), MSc in Tissue Engineering, 2016 onwards. |
Year(s) Of Engagement Activity | 2013,2014,2015,2016,2017,2018 |
Description | Podcast interview "Stem Cells @ Lunch Digested" |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Prof Francesco Saverio Tedesco, Professor of Neuromuscular Biology and Regenerative Medicine at University College London, is interviewed by researcher Dr Davide Danovi. Francesco talks about his work using stem cells to understand and develop new therapies for muscular diseases such as muscular dystrophy. He speaks about the balance between his professions as a clinician and a scientist, and how this supports the translational goal of his research. |
Year(s) Of Engagement Activity | 2021 |
URL | https://soundcloud.com/user-563815853/episode-127-prof-francesco-saverio-tedesco-seeing-patients-giv... |
Description | Seminar to general paediatricians |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Professional Practitioners |
Results and Impact | ? Weekly paediatric teaching session, University College Hospital, London, UK, Nov 2016. The clinicians reported increased interest in the subject. |
Year(s) Of Engagement Activity | 2016 |
Description | Speaker at Inaugural UK Regenerative Medicine Conference 20 / 21 September 2016 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Follow-up discussions with academics and industry that have led to new collaborations. |
Year(s) Of Engagement Activity | 2016 |
Description | UCB Discovery Biology Science Day |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Keynote lecture on the TIPS microparticle technology at the UCB Discovery Biology Science Day. UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions. |
Year(s) Of Engagement Activity | 2016 |
Description | keynote speaker at TERMIS conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Tissue Engineering and Regenerative Medicine International Society (TERMIS) World Congress, Kyoto (JP), Sep 2018 (keynote speaker) |
Year(s) Of Engagement Activity | 2018 |